The researchers found 25.6 million people aged 15 to 49 years had new HSV-2 infections and 519.5 million (13.3%) had existing (prevalent) HSV-2 infections globally in 2020. (HealthDay News) — The ...
GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy ...
– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...
GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the likes of Moderna and BioNTech. The recombinant protein vaccine, dubbed ...
Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020. (HealthDay News) — The incidence and prevalence of genital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback